H&K (ENXTPA:MLHK) Jumped, So What Is Behind The Move?

The U.S. Department of Homeland Security proposal to scrap the 60 day H-1B grace period has drawn investor attention to H&K (ENXTPA:MLHK), given potential implications for specialized talent in its international operations.

See our latest analysis for H&K.

The H&K share price closed at €35.0 after a 1 day share price return of 7.03%, yet the stock is still down 20.45% on a year to date basis and the 1 year total shareholder return has declined 47.26%, which indicates that recent momentum is recovering from a much weaker long term performance.

If this kind of sharp short term move has your attention, it can be helpful to compare H&K with other defence related manufacturers and broaden your watchlist using the 108 top founder-led companies

After a 7.03% jump yet deep 1-year and multi-year declines, H&K now sits at an awkward middle ground. Is this a window to start building a position, or does waiting for a cheaper entry make more sense once valuation is clearer?

Price-to-Earnings of 23.7x for H&K: Is it justified?

On a P/E basis, H&K trades at 23.7x earnings, which is lower than several peer benchmarks even after the recent move to €35. This indicates a valuation that is below many comparable defence stocks rather than stretched by the latest rebound.

The P/E multiple compares a company’s share price with its earnings per share. For a defence manufacturer like H&K, investors often watch this closely because earnings can be influenced by contract timing, defence budgets, and capital intensity. The P/E helps frame how much the market is paying for each unit of current profit.

H&K’s P/E of 23.7x sits below the Aerospace & Defense industry average of 32.4x, the peer average of 41.4x, and the wider European Aerospace & Defense average of 35.7x. That is a sizeable gap and suggests the market is pricing H&K’s earnings at a discount compared to sector peers.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Earnings of 23.7x (UNDERVALUED)

However, H&K’s long slide in multi year shareholder returns, along with uncertainty around specialist talent mobility, could still weigh on investor confidence and contract execution.

Find out about the key risks to this H&K narrative.

Another View on H&K Using Cash Flows

While the current P/E suggests H&K might be inexpensive compared with peers, the SWS DCF model points in the opposite direction. At €35 per share, the stock is reported to trade far above an estimated future cash flow value of €1.16, which implies a very rich price for the underlying cash generation.

This clash between earnings based and cash flow based signals raises an important question for investors. Should more weight be given to today’s earnings strength or to a model that prices in more conservative long term cash flows and risk assumptions? Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out H&K for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 264 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals around H&K’s valuation and outlook can feel unclear, so it makes sense to review the underlying data yourself and decide how it stacks up. To balance the concerns and potential upside, take a closer look at the 2 key rewards and 1 important warning sign

Looking for more ideas beyond H&K?

If H&K has sharpened your focus on valuation and risk, it can be useful to scan other stocks that may align more closely with your investing style.

• Target companies that look mispriced by comparing fundamentals with the 264 high quality undervalued stocks.
• Strengthen your income stream by focusing on reliable payers through the 435 dividend fortresses.
• Prioritise resilience and sleep easier at night with the 289 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com